Leukotrienes C4 and D4 sensitize human neutrophils for hyperreactivity to chemoattractants

Inflammation Research

Volumn 58, Issue 5, 2009, Pages 263-268

  Theron, A J ^a   Gravett, C M ^a   Steel, H C ^a   Tintinger, G R ^a   Feldman, C ^b   Anderson, R ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cysteinyl leukotrienes; Elastase; MMP 8; Montelukast; Neutrophils; Superoxide

Indexed keywords

CALCIUM; CHEMOATTRACTANT; ELASTASE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LEUKOTRIENE C4; LEUKOTRIENE D4; MONTELUKAST; NEUTROPHIL COLLAGENASE; SUPEROXIDE; ACETIC ACID DERIVATIVE; CHEMOTACTIC FACTOR; DRUG DERIVATIVE; FLUORESCENT DYE; FURA 2; FURA 2 ACETOXYMETHYL ESTER; FURA-2-AM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PANCREATIC ELASTASE; QUINOLINE DERIVATIVE;

ARTICLE; ATOPY; CALCIUM MOBILIZATION; CELL ACTIVATION; CELL ACTIVITY; CHEMOSENSITIZATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; NORMAL HUMAN; PROTEIN EXPRESSION; ADULT; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; METABOLISM;

ACETATES; ADULT; CHEMOTACTIC FACTORS; FLUORESCENT DYES; FURA-2; HUMANS; INFLAMMATION; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE C4; LEUKOTRIENE D4; MATRIX METALLOPROTEINASE 8; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PANCREATIC ELASTASE; QUINOLINES; SUPEROXIDES;

EID: 67349132463     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-008-8049-y     Document Type: Article

References (24)

1. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007; 357: 1841-54.
2. 4, histamine and bradykinin on cytosolic calcium, concentrations and adhesiveness of endothelial cells and neutrophils. Clin Exp Immunol 1996; 103: 454-60.
3. 4 in human polymorphonuclear leukocytes. Blood 1999; 93: 1399-405.
4. Zhu J, Qiu YS, Figueroa DJ, Bandi V, Galczenki H, Hamada K, et al. Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 2005; 33: 531-40.
5. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium. (MK-0476) in healthy males and females. Pharm Res 1996; 13: 445-8.
6. Knorr B, Holland S, Schwartz J, Douglas Rogers J, Reiss TF. Clinical pharmacology of montelukast. Clin. Exper Allergy Rev 2001; 1: 254-60.
7. 2+ indicators with greatly improved fluorescent properties. J Biol Chem 1985; 260: 3440-50.
8. Minkenberg I, Ferber E. Lucigenin-dependent chemiluminescence as a new assay for NADPH-oxidase activity in particulate fractions of human polymorphonuclear leukocytes. J Immunol Methods 1984; 71: 61-7.
9. Beatty K, Robertie P, Senior RM, Travis J. Determination of oxidized alpha-1-proteinase inhibitor in serum. J Lab Clin Med 1982; 100: 186-92.
10. Capra V. Molecular and functional aspects of human cysteinyl leukotriene receptors. Pharm. Res 2004; 50: 1-11.
11. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution functions in immune and inflammatory responses. J Immunol 2004; 173: 1503-10.
12. Naik S, Billington CK, Pascual RM, Deshpande D, Stefano F, Kohout T, et al. Regulation of cysteinyl leukotriene type 1 receptor internalization and signalling. J Biol Chem 2005; 280: 8722-32.
13. 1. Blood 2001; 97: 3433-40.
14. Lew PD, Monod A, Waldvogen FA, Pozzan T. Role of cytosolic free calcium and phospholipase C in leukotriene-B4-stimulated secretion in human neutrophils. Comparison with the chemotactic peptide formyl-methionyl-leucyl-phenylalanine. Eur J Biochem 1987; 162: 161-8.
15. Ramires R, Caiaffa MF, Tursi A, Haeggstrom JZ, Macchia L. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun 2004; 324: 815-21.
16. Hallett MB, Llyods D. Neutrophil priming: the cellular signals that say 'amber' but not 'green.' Immunol Today 1995; 16: 264-8.
17. 47phox serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest 2006; 116: 2033-43.
18. Suzuki T, Wang W, Lin JT, Shirato K, Mitsuhashi H, Inoue H. Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Am J Respir Crit Care Med. 1996; 153: 1405-11
19. Prikk K, Maisi P, Pirilä E, Reintam MA, Salo T, Sorsa T, Sepper R. Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab Invest 2002; 82: 1535-45
20. Sugiura H, Ichinose M. Oxidative and nitrative stress in bronchial asthma. Antioxid Redox Signal; 2008; 10: 785-97
21. Hiraguchi Y, Nagao M, Hosoki K, Tokuda R, Fujisawa T. Neutrophil proteases activate eosinophil function in vitro. Int Arch Allergy Immunol. 2008; 146: 16-21
22. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorganioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med 2005; 99: 444-50.
23. Rubinstein I, Kumar B, Schriever C. Long-term montelukast therapy in moderate to severe COPD - a preliminary observation. Respir Med 2004; 98: 134-8.
24. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin. Immunol 2007; 119: 1055-62.